

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A transgenic ~~or somatic recombinant non-human animal~~ mouse whose genome comprises a polynucleotide encoding a soluble marker protein functionally linked to a regulatory sequence of an endogenous gene encoding E-selectin wherein the polynucleotide encoding a soluble marker protein is inserted into a region of an E-selectin gene of a chromosomal E-selectin allele of the mouse which is between a transcription start site and a translation start site of the E-selectin gene, wherein the mouse expresses the soluble marker protein by endothelial cells and the expression is regulatable by chemical or physical stimulus, and wherein the polynucleotide comprises SEQ ID NO:11 or SEQ ID NO:12.

Claims 2-8 (canceled).

Claim 9 (withdrawn-currently amended): A transgenic knockout mouse which is homozygous or heterozygous for a chromosomal E-selectin allele comprising a genetic construct comprising a soluble reporter transgene, said soluble reporter transgene being under the control of the promoter of the E-selectin gene of said chromosomal E-selectin allele, and said genetic construct being inserted into a region which is between a transcription start site and a translation start site of the E-selectin gene of the chromosomal E-selectin allele wherein the soluble marker protein is secreted alkaline phosphatase. [[.]]

Claim 10 (canceled).

Claim 11 (withdrawn-currently amended): A transgenic mouse according to claim 9 wherein the genetic construct comprises SEQ ID NO:11 or SEQ ID NO:12.

Claim 12 (withdrawn): An isolated cell derived from the transgenic mouse according to claim 9.

Claim 13 (withdrawn): DNA having SEQ ID NO:9 or SEQ ID NO:10.

Claim 14 (withdrawn): A method of screening for an agent having therapeutic utility, comprising:

(a) administering the agent to a transgenic or somatic recombinant non-human animal according to claim 1;

(b) monitoring marker concentration in a body fluid of said animal, and

(c) comparing said marker concentration to the concentration of marker in an untreated transgenic or somatic recombinant non-human animal, an elevated level being indicative of the therapeutic utility of the agent.

Claim 15 (withdrawn): A method of screening for an agent which is a modulator of E-selectin expression, comprising:

(a) administering the agent to a transgenic or somatic recombinant non-human animal according to claim 1,

(b) monitoring marker concentration in a body fluid, and

(c) comparing said marker concentration to the concentration of marker in an untreated transgenic or somatic recombinant non-human animal, an modulated level being indicative of the capability of said agent of modulating E-selectin expression.

Claim 16 (withdrawn): A novel modulator of E-selectin expression identified by a method according to claim 15.

Claim 17 (withdrawn): A method for treating a patient suffering from an inflammatory, thrombotic, ischaemic or neoplastic condition or from transplant rejection comprising administering to the patient a pharmaceutically effective amount of a modulator according to claim 16.

Claim 18 (withdrawn): A method of monitoring disease progression comprising:

(a) crossing a transgenic mouse according to claim 1 with an animal strain used as an animal model,

(b) recovering at least one offspring, and

(c) monitoring at least one offspring for disease progression in relation to marker concentration in a body fluid.